Lifastuzumab vedotin explained

Lifastuzumab vedotin (INN;[1] development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.[2]

This drug was developed by Genentech/Roche.

References

  1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 . WHO Drug Information . 27 . 4 . 2013 .
  2. http://www.ama-assn.org/resources/doc/usan/x-pub/lifastuzumab-vedotin.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lifastuzumab vedotin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.